SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In preclinical models of MASLD, SGLT2 inhibition has been shown to improve lipid metabolism, along with desirable inflammatory responses, reduced oxidative stress, and even apoptosis [78–80].